Cargando…
Delivery Strategies for mRNA Vaccines
The therapeutic potential for messenger RNA (mRNA) in infectious diseases and cancer was first realized almost three decades ago, but only in 2018 did the first lipid nanoparticle-based small interfering RNA (siRNA) therapy reach the market with the United States Food and Drug Administration (FDA) a...
Autores principales: | Ramachandran, Sivakumar, Satapathy, Soumya Ranjan, Dutta, Tathagata |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8801198/ https://www.ncbi.nlm.nih.gov/pubmed/35094366 http://dx.doi.org/10.1007/s40290-021-00417-5 |
Ejemplares similares
-
mRNA Vaccine Platform: mRNA Production and Delivery
por: Litvinova, V. R., et al.
Publicado: (2023) -
The Delivery of mRNA Vaccines for Therapeutics
por: Nitika,, et al.
Publicado: (2022) -
Nanomaterial Delivery Systems for mRNA Vaccines
por: Buschmann, Michael D., et al.
Publicado: (2021) -
Opportunities and Challenges in the Delivery of mRNA-Based Vaccines
por: Wadhwa, Abishek, et al.
Publicado: (2020) -
Towards Targeted Delivery Systems: Ligand Conjugation Strategies for mRNA Nanoparticle Tumor Vaccines
por: Phua, Kyle K. L.
Publicado: (2015)